After Series V: How Much Financing Oxygen Is Actually Left at Giron
Series V did not leave Giron with a covenant problem. It left the parent company with a tenor problem: just NIS 39.4 million of cash and short-term investments at solo level against NIS 236.4 million of one-year contractual obligations, which means the remaining financing oxygen now depends on operating cash flow, upstream cash from subsidiaries, and refinancing the short bank bridge.
The main article argued that Giron’s 2025 bottleneck was no longer the property story. It was the financing story. This follow-up isolates the question that remains after the full repayment of Series V: how much oxygen is actually left at the parent-company level, how much of it comes from real recurring cash generation, and how much of it is simply the next test being pushed forward.
The first message is that covenants are not the problem. The second message is that liquidity still is. Giron ends the year with about NIS 1.04 billion of equity and a 51.6% equity-to-assets ratio, far above the floors in Series Z and Series H. But the parent company ends 2025 with NIS 25.8 million of cash, NIS 13.6 million of short-term investments, a solo working-capital deficit of about NIS 132.6 million, and a NIS 165 million short-term bank bridge that matures in November and December 2026. That is not a balance-sheet squeeze. It is a time window.
The third message is that Giron’s financing oxygen no longer sits in a large idle cash cushion at the public-company level. It has to come from three sources combined: operating cash flow, upstream cash from subsidiaries, and refinancing the short bridge back into longer-duration funding. The company explicitly says there are no restrictions on transfers within the group, and in 2025 it did in fact receive NIS 46.9 million of dividends from a held company. But that is exactly the point: liquidity at the listed-company layer depends on a continued lift from below and on reopening the debt market from above.
The fourth message is that timing became more sensitive precisely now. The management change was first presented on January 22, 2026, approved on February 5, 2026, and took effect on February 8, 2026, when Ron Avidan became CEO and Avi Roichman moved to active chairman. This is not a change-of-control event, but it is a change in the execution chain exactly when the short bank line starts to matter.
| Focus area | End-2025 number | Why it matters |
|---|---|---|
| Consolidated equity | NIS 1.04 billion | Covenant room is wide, so the story is not about breaching trust-deed floors |
| Equity-to-assets ratio | 51.6% | A large buffer over both 25% and 27% thresholds |
| Solo liquid assets | NIS 39.4 million | This is the immediate hard-cash layer at the parent |
| Solo contractual obligations within one year | NIS 236.4 million | The near wall remains much larger than the liquid layer |
| Short-term bank credit | NIS 165.0 million | This is the debt that bought time after Series V was repaid |
The Real Gap Sits At The Parent, Not In The Consolidated Picture
The consolidated view can still look manageable at first glance. Consolidated cash and short-term investments stand at NIS 57.8 million, and operating cash flow reached NIS 80.1 million. But bond debt and bank debt are not serviced by the portfolio as an abstract asset base. They are serviced by the parent company.
At solo level, the picture is sharper. Current assets total NIS 89.2 million, but more than half of that is not hard cash. It is current balances with held companies of NIS 47.1 million. The harder liquid layer is NIS 25.8 million of cash plus NIS 13.6 million of short-term investments. Against that, current liabilities amount to NIS 221.8 million, leaving a solo working-capital deficit of about NIS 132.6 million.
The more important number still is the parent company’s contractual-liquidity table. Obligations due within one year amount to NIS 236.4 million on an undiscounted basis. Of that, NIS 174.5 million is bank credit, NIS 53.7 million is bonds including interest, and roughly NIS 8.1 million is suppliers and other payables. This is no longer a question of whether the company owns valuable assets. It is a question of timing and funding sources.
This is the core of the thesis. Repaying Series V did not solve the funding problem. It replaced it. Instead of a bond layer that matured on December 31, 2025, Giron now carries a bank bridge that matures less than a year after its approval. In plain terms, Giron bought time. It did not yet buy a solution.
Even a full repeat of the parent company’s 2025 solo operating cash flow, NIS 80.4 million, would not by itself solve that picture. Operating cash flow matters because it shows that the parent layer is not empty. It is still far smaller than the one-year maturity table. The financing oxygen is therefore real, but it is not deep.
Covenant Headroom Is Wide, Which Means The Risk Moved To Tenor
Anyone reading Giron only through the trust deeds could miss the main point. The covenants in Series Z and Series H are nowhere near pressure. In Series H, the stricter of the two, the hard equity floor is NIS 385 million and the interest-step floor is NIS 405 million. Actual consolidated equity at year-end 2025 is about NIS 1.04 billion. The equity-to-assets ratio stands at 51.6% versus a 25% hard floor and a 27% interest-step threshold.
Series Z is looser still. The bonds are still rated A1 with a stable outlook, and the company says all of its properties are unencumbered. The short bank lines drawn in December 2025 are unsecured and carry no financial covenants. On paper, that sounds comfortable.
But that comfort can mislead. Covenant room is not financing room. It tells you the company is far from breaching its trust deeds. It does not tell you that it can comfortably sit with NIS 165 million of short bank debt without reopening the funding market. That is exactly the shift that matters here: the risk moved from “can Giron borrow” to “at what price, for what tenor, and how quickly can it term this out.”
That is also why the company keeps several doors open at once. It has a shelf prospectus in place until August 6, 2027. It has unencumbered assets valued at about NIS 1.908 billion. It still has a rating that was not cut. In other words, the refinancing path exists. What has not yet been proven is the set of terms on which that path will close.
Upstream Capacity Exists, But It Is Not A Substitute For Refinancing
One of the most important clues in Giron sits in the solo section. During 2025 the parent company received NIS 46.9 million of dividends from a held company. As of December 31, 2025 it also held receivables from held companies of NIS 205.0 million, of which NIS 47.1 million was current and NIS 157.9 million non-current. Against that, it also carried NIS 60.1 million of non-current payables to held companies.
The implication cuts both ways. On one hand, cash inside the group is not formally trapped. The company explicitly says there are no restrictions on transfers within the group, and the NIS 46.9 million dividend proves that the lift to the parent does work. On the other hand, that also means the parent’s liquidity depends on subsidiaries continuing to generate enough surplus and continue sending it upward, not only on the existence of a large real-estate portfolio.
Dividend capacity toward shareholders is not the immediate legal bottleneck either. After incorporating the trust-deed restrictions, distributable profits still amount to roughly NIS 165 million. Formally, that is room. Economically, it is a different story. In 2025 the company also drew NIS 165 million of short bank debt to repay Series V, still paid NIS 20 million of dividends to shareholders, and still ended the year with only NIS 39.4 million of cash and short-term investments at solo level. The right question is therefore not “is a distribution allowed,” but “what capital use actually leaves enough oxygen until the next refinancing closes.”
That is also why the solo layer matters more than gross asset value. A large asset base creates optionality for secured borrowing, bond issuance, or bank funding. It does not service 2026 on its own. The next year will be serviced by cash, subsidiary dividends, and the speed at which the market agrees to replace short bank debt with longer-dated funding.
The Management Transition Does Not Break The Thesis, But It Does Raise The Execution Test
Giron does not enter 2026 with the same management structure it used to finish 2025. On January 22, 2026 the company reported its intention to appoint Ron Avidan as CEO and Avi Roichman as active chairman. On February 5, 2026 the general meeting approved those appointments and the related services agreement, and they became effective on February 8, 2026.
This is not an event that signals immediate stress. There is no control change, no rating hit, and no statement in the filing that financing access was lost. But it is a change in the execution chain exactly when the company needs to do three things at once: preserve operating cash flow, continue to upstream cash from subsidiaries, and refinance the NIS 165 million short bank bridge before November and December 2026.
The detail that sharpens the execution point is the new service structure. Roichman and Avidan provide the company with active-chairman and CEO services through Destiny, each at a 75% position. That is not evidence that the structure will fail. It is a reason to read 2026 as a funding-and-execution test rather than as a glide year.
In a bond-only issuer, without an equity screen to distract the read, investors will judge this story through the debt layer. That means any delay in refinancing, any slowdown in upstream cash from subsidiaries, or any overly aggressive capital use will show up faster through funding conditions than through property values.
Conclusion
After Series V, Giron was not left without oxygen. It was left with shorter, more expensive, and more execution-dependent oxygen. The covenants are remote, the bond rating is stable, and there is no blanket encumbrance on the property portfolio. That means the company still has a credible refinancing path.
But that path is not closed yet. At the parent-company level, NIS 39.4 million of cash and short-term investments stand against NIS 236.4 million of contractual obligations within one year. That gap is meant to be closed by operating cash flow, subsidiary dividends and intercompany balances, and above all by replacing the NIS 165 million short bank bridge with longer-duration funding. That is the real 2026 test.
If Giron terms out the short debt on reasonable terms, preserves upstream cash from subsidiaries, and avoids unnecessary capital leakage, the Series V repayment will look like a tactical bridge in hindsight. If not, the market will discover quickly that high property values and wide covenant buffers are not a substitute for real liquidity runway.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.